Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction

Circulation

Volumn 108, Issue 16 SUPPL., 2003, Pages

  Braunwald, Eugene ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angina; Angioplasty; Antioxidants; Myocardial infarction; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CATHETERIZATION; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; ELECTROCARDIOGRAM; EXERCISE TEST; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

EID: 18844466073     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.0000086952.14979.32     Document Type: Conference Paper

References (75)

1. Conti CR, Greene B, Pitt B, et al. Coronary surgery in unstable angina pectoris (abstract). Circulation. 1971;44(suppl II):II-154.
2. Fowler NO. "Preinfarctional" angina: A need for an objective definition and for a controlled clinial trial of its management. Circulation. 1971;44:755-758.
3. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: Diagnosis and management. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service, US Department of Health and Human Services; 1994:1; Publication No. 94-0602.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina non-ST segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062; also Management of patients with unstable angina and non-ST-segment elevation myocardial infarction update. 2002 http://www.acc.org/clinical/guidelines/unstable/update_explantext.htm.
5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina non-ST segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062; also Management of patients with unstable angina and non-ST-segment elevation myocardial infarction update. 2002 http://www.acc.org/clinical/guidelines/unstable/update_explantext.htm.
6. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article. Circulation. 2002;106:1893-1900.
7. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force of the European Society of Cardiology. Eur Heart J. 2002;23:1809-1840.
8. Braunwald E. Unstable angina - A classification. Circulation. 1989;80:410-414.
9. Scirica BM, Cannon CP, McCabe CH, et al. Prognosis in the Thrombolysis in Myocardial Ischemia III Registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002;90:821-826.
10. Canto JG, Fincher C, Kiefe CI, et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol. 2002;90:248-253.
11. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713.
12. Cannon CP, McCabe CH, Stone PH, et al., for the TIMI III Registry ECG Ancillary Study Investigators. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: Results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol. 1997;30:133-140.
13. Kaul P, Newby LK, Fu Y, et al. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003;41:371-380.
14. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation: Results from an international trial of 9461 patients. The PURSUIT investigators. Circulation. 2000;101:2557-2567.
15. Antman EM, Cohen M, Bemink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
16. Morrow DA, Antman EM, Snapinn S, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223-229.
17. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
18. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-1626.
19. Scirica BM, Cannon CP, Antman EM, et al. Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk score for unstable angina and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002;90:303-305.
20. Sabatine MS, McCabe CH, Morrow DA, et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002;143:966-970.
21. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A global utilization of strategies to open occluded arteries (GUSTO) -IV substudy. Circulation. 2003;108:275-281.
22. Januzzi JL, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation. 2002;105:2361-2366.
23. Januzzi JL, Cannon CP, DiBattiste PM, et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002;90:1246-1249.
24. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346:2047-2052.
25. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain index. Circulation. 2001;103:1832-1837.
26. Sabatine MS, Morrow DA, deLemos J, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.
27. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation. 2003;108:250-252.
28. nd ed. St. Louis: Mosby-Year Book; 1995:525-541.
29. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
30. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
31. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol. 1999;83:1147-1151.
32. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
33. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966-972.
34. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol. 2002;40:218-219.
35. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231-237.
36. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527-533.
37. Steinhubl SR, Berger PD, Mann JT III, et al., for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420.
38. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomized trial. Lancet. 2001;357:1915-1924.
39. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
40. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: Insights from the Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin (PURSUIT) trial. Circulation. 2000;102:1093-1100.
41. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 2003;289:331-342.
42. Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
43. Antman EM, McCabe CH, Gurfinkel EP, et al., for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation. 1999;100:1593-1601.
44. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI 11B ESSENCE meta-analysis. Circulation. 1999;100:1602-1608.
45. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J. 2002;144:615-624.
46. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003;107:238-244.
47. The SYNERGY Executive Committee. Superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors. Am Heart J. 2002;143:952-960.
48. Blazing MA, deLemos JA, Dyke CK, et al. The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of an early aggressive simvastatin therapy. Am Heart J. 2001;142:211-217.
49. Michalis LK, Katsouras C, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: The EVET trial. Am Heart J. 2003;146:304-310.
50. TIMI III Study Group. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial. Circulation. 1994;89:1545-1556.
51. Stone PH, Thompson B, Zaret BL, et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q-wave MI: A TIMI-IIIB database study. Eur Heart J. 1999;20:1084-1093.
52. Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol. 2001;38:969-976.
53. Boden WE, O'Roueke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338:1785-1792.
54. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: The FRISC II invasive randomized trial. Lancet. 2000;356:9-16.
55. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1905-1907.
56. Fox KAA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or noa-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Lancet. 2002;360:743-751.
57. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000;21:1502-1513.
58. Stone PH, Thompson B, Anderson HV, et al., for the TIMI III Registry Study Group. Influence of race, sex and age on management of unstable angina and non-Q-wave myocardial infarction. The TIMI III Registry. JAMA. 1996;275:1104-1112.
59. Hochman JS, McCabe CH, Stone PH, et al., for the TIMI Investigators. Outcome and profile of women and men presenting with acute coronary syndromes: A report from TIMI IIIB. J Am Coll Cardiol. 1997;30:141-148.
60. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288:3124-3129.
61. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. N Engl J Med. 1998;339:436-443.
62. Hochman JS, Tamis-Holland JE. Acute coronary syndromes. Does sex matter? JAMA. 2002;288:3161-3164.
63. Mueller CM, Neumann F-J, Roskamm H, et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:245-250.
64. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline update for the management of patients with chronic stable angina - Summary article. Circulation. 2003;107:149-158.
65. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet. 2001;357:1063-1068.
66. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436.
67. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002;287:3087-3095.
68. Michels KB, Braunwald E. Estimating treatment effects from observational data: Dissonant and resonant notes from the SYMPHONY trial. JAMA. 2002;287:3130-3132.
69. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study, a randomized controlled trial. JAMA. 2001;285:1711-1718.
70. Cannon CP, McCabe CH, Belder R, et al. Pravastatin of atorvastatin evaluation and infection therapy (PROVE IT) - TIMI 22 trial: Rationale and design. Am J Cardiol. 2002;89:860-861.
71. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
72. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet. 2002;360:7-22.
73. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now. Circulation. 2001;103:2768-2770.
74. Hccschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
75. Serruys PW, deFeyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;287:3215-3222.